Infectious Disease Self-Assessment Program (IDSAP) Book 1: HIV and Hepatitis (Cert #L199270)

ACPE Numbers: Various – see listing below
Content Release Date: 5/15/19
Expiration Dates: 11/15/19
Activity Type: Application-based
CE Credits: 15.0 hours 

Accreditation for Pharmacists

The American College of Clinical Pharmacy and American Society of Health-System Pharmacists are accredited by the Accreditation Council for Pharmacy Education as providers of continuing pharmacy education.

Target Audience

The target audience for IDSAP 2019 Book 1 (HIV and Hepatitis) is board certified and advanced-level infectious disease pharmacists involved in the management of patients with HIV and hepatitis, including pharmacotherapy, prevention, and opportunistic infections. 

Activity Overview

This course is intended for board certified pharmacists in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS). The course consists of 3 learning modules (see table below) and provides up to 15.0 hours of continuing pharmacy education and/or recertification credit. 

Learners will be required to review the content and complete the associated online assessments. The learner must be able to correctly answer the questions based upon their interpretation of the content, as well as “baseline specialty specific knowledge and/or easily retrievable information.” For purposes of this course, “baseline specialty specific knowledge and/or easily retrievable information” is defined as product labeling and well-established standards of practice in the specialty practice. 

These activities are part of the ASHP and ACCP professional development program for BCIDP recertification approved by the BPS.  

Recertification Credit*

Board certified pharmacists are eligible to receive up to 15.0 hours of recertification credit for completing this course. To earn recertification credit, learners must review the activity content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed. You are allowed only one attempt to successfully complete this assessment.

Learning Activity

ACPE Number

Credit Hours

*Assessment Pass Point

IDSAP 2019 Book 1 (HIV and Hepatitis) - HIV I




IDSAP 2019 Book 1 (HIV and Hepatitis) - Hepatitis I




IDSAP 2019 Book 1 (HIV and Hepatitis) - HIV and Hepatitis I






IDSAP 2019 Book 1 (HIV and Hepatitis) - HIV I

  • Apply knowledge of the mechanism of action, dosing recommendations, adverse effects, and major drug-drug interactions of the most recent FDA approved antiretroviral agents/formulations to determine appropriate therapy for a patient living with HIV.
  • Justify the changes made in 2016 DHHS guidelines through current guidelines with regards to antiretroviral treatment initiation.
  • Evaluate a patient for appropriateness of new or emerging treatment strategies including two drug therapy, treatment simplification, and long acting antiretroviral therapy.
  • Describe updates in antiretroviral therapy in special populations.
  • Design a meningococcal vaccination recommendation and zoster vaccination regimen for a patient living with HIV.
  • Apply HIV testing recommendations to patient scenarios and interpret test results based on testing windows.
  • Assess HIV risk and evaluate test results to determine if pre-exposure prophylaxis (PrEP) is appropriate for a patient.
  • Distinguish candidates for postexposure prophylaxis (PEP) and develop a PEP treatment plan based on patient characteristics.
  • Design a plan to transition a patient from PEP to PrEP.
  • Design an appropriate treatment regimen and monitoring plan, on the basis of disease severity, for a patient with Pneumocystis pneumonia.
  • Evaluate a treatment regimen for toxoplasmosis disease on the basis of its therapeutic appropriateness and practical feasibility.
  • Assess the need for prophylaxis or treatment in a patient with disseminated Mycobacterium avium complex disease.
  • Design an appropriate treatment regimen for the patient with latent tuberculosis infection.
  • Evaluate potential advantages and risks of primary prophylaxis for cryptococcosis.
  • Design a treatment regimen and monitoring plan for the patient with cryptococcal meningitis according to the phase of therapy (induction, consolidation, or maintenance).
  • Justify the timing of antiretroviral therapy initiation in a patient with cryptococcal meningitis.
  • Justify the use of primary prophylaxis for cytomegalovirus (CMV) disease.
  • Design an appropriate treatment regimen and monitoring plan for CMV disease. 

IDSAP 2019 Book 1 (HIV and Hepatitis) - Hepatitis I

  • Justify vaccination for preventing hepatitis A virus (HAV) and hepatitis B virus (HBV) infection.
  • Design interventions for managing HAV and hepatitis D virus.
  • Apply national guideline–based treatment strategies to design patient-specific therapy for HBV.
  • Develop drug-related patient education and counseling for pharmacologic therapies used in managing HBV.
  • Assess patients for risk of HBV reactivation
  • Given clinical patient and laboratory data, design a pharmacotherapeutic treatment plan for the patient with chronic hepatitis C virus (HCV) infection.
  • For each oral direct-acting HCV antiviral, evaluate its role in HCV therapy, major drug-drug interactions, and need for concomitant use of ribavirin.
  • Design pharmacotherapy for special patient populations with chronic HCV infections. 

IDSAP 2019 Book 1 (HIV and Hepatitis) - HIV and Hepatitis I

  • Distinguish the main mechanisms of interactions for the different classes of antiretrovirals and direct-acting antiviral (DAA) agents for hepatitis C virus (HCV).
  • Evaluate differences between the boosting agents ritonavir and cobicistat with respect to drug interaction potential.
  • Evaluate and manage drug interactions between antiretrovirals, DAAs, and commonly used co-medications or when switching or simplifying antiretroviral regimens.
  • Assess the value of specialized HIV and HCV drug interaction resources versus standard drug interaction references.
  • Distinguish between telehealth, telemedicine, and telepharmacy.
  • Evaluate key clinical and technical components in implementing a successful HIV and HCV telemedicine program.
  • Resolve reimbursement and billing issues associated with the implementation of a telehealth service.
  • Analyze the legal and regulatory factors of telehealth and their implications in clinical pharmacy practice. 


Melissa Badowski, Pharm.D., MPH, FCCP, BCIDP, BCPS, AAHIVP
Clinical Associate Professor
Department of Pharmacy Practice
University of Illinois at Chicago College of Pharmacy
Chicago, Illinois 

Camille Beauduy, Pharm.D., BCPS
Clinical Pharmacist, Infectious Diseases
Zuckerberg San Francisco General Hospital and Trauma Center
San Francisco Department of Public Health
San Francisco, California 

Juliana Chan, Pharm.D., FCCP, BCACP
Clinical Associate Professor, Clinical Pharmacist
Pharmacy Practice, Sections of Hepatology, Digestive Diseases and Nutrition
University of Illinois at Chicago
Chicago, Illinois 

Jennifer Cocohoba, Pharm.D., MAS, BCPS
Professor of Clinical Pharmacy
Clinical Pharmacy Department
University of California San Francisco, School of Pharmacy
San Francisco, California 

Paulina Deming, Pharm.D., PhC
Associate Professor
Department of Pharmacy Practice and Administrative Sciences
College of Pharmacy
Assistant Director
Viral Hepatitis Programs, ECHO Institute
University of New Mexico Health Sciences Center
Albuquerque, New Mexico 

David E. Koren, Pharm.D., BCPS, AAHIVP
Clinical Pharmacist Specialist – Infectious Diseases/HIV
Department of Pharmacy Services
Temple University Hospital
Philadelphia, Pennsylvania 

Christina M. Madison, Pharm.D., FCCP, BCACP, AAHIVP
Associate Professor of Pharmacy Practice
College of Pharmacy
Roseman University of Health Sciences
Henderson, Nevada 

Michelle T. Martin, Pharm.D., FCCP, BCPS, BCACP
Clinical Associate Professor
Department of Pharmacy Practice
University of Illinois at Chicago College of Pharmacy
Clinical Pharmacist
Bobbie and Marvin Fink Family Liver Clinic
University of Illinois Hospital and Health Sciences System
Chicago, Illinois 

Sarah M. Michienzi, Pharm.D., BCPS, AAHIVP
Clinical Assistant Professor
Pharmacy Practice, Infectious Diseases Pharmacotherapy Section
University of Illinois at Chicago College of Pharmacy
Chicago, Illinois 

Alice Tseng, Pharm.D., FCSHP, AAHIVP
HIV Pharmacotherapy Specialist
Immunodeficiency Clinic
Toronto General Hospital
Associate Professor
Leslie Dan Faculty of Pharmacy, University of Toronto
Toronto, Ontario, Canada 

Elyse L. Tung, Pharm.D., BCACP
Director of Clinical Services
Kelley-Ross Pharmacy Group
Clinical Assistant Professor
School of Pharmacy
University of Washington
Seattle, Washington 

Series Editors

Elizabeth S. Dodds Ashley, Pharm.D., MHS, BCPS
Associate Professor of Medicine
Division of Infectious Diseases
Duke University School of Medicine
Director of Operations
Duke Antimicrobial Stewardship Outreach Network (DASON)
Durham, North Carolina 

Alan E. Gross, Pharm.D., BCPS, BCIDP
Clinical Assistant Professor
Department of Pharmacy Practice
University of Illinois at Chicago College of Pharmacy
Infectious Diseases Pharmacist
Hospital Pharmacy Services
University of Illinois Hospital and Health Sciences System
Chicago, Illinois 

Faculty Panel Chair

Betty J. Dong, Pharm.D., FCCP, FASHP, FAPHA, AAHIVP 


Daniel S. Baker, Pharm.D., BCPS, BCCCP, BCIDP
Linda W. Cheung, Pharm.D., MBA, BCPS
Alyssa Christensen, Pharm.D., BCIDP
Monika N. Daftary, Pharm.D., BCPS-AQ ID, AAHIVP
Kierra M. Dotson, Pharm.D., BCPS
Linda Dresser, Pharm.D.
Islam M. Ghazi, Pharm.D., MSc,  BCPS, BCACP
Zhe Han, Pharm.D., BCPS, BCIDP
Jennifer J. Kiser, Pharm.D., Ph.D.
Wesley D. Kufel, Pharm.D., BCIDP, BCPS, AAHIVP
Michelle D. Liedtke, Pharm.D., BCPS, AAHIVP
Edo-abasi Umoh McGee, Pharm.D., BCPS
Navaneeth Narayanan, Pharm.D., MPH, BCPS
Neha Sheth Pandit, Pharm.D., BCPS, AAHIVP
Patricia Poole, Pharm.D., BCPS-AQ ID, AAHIVP
Kimberly K. Scarsi, Pharm.D., MS, FCCP, BCPS-AQ ID
Jason J. Schafer, Pharm.D., MPH, BCPS-AQ ID, BCIDP, AAHIVP
Bhavik M. Shah, Pharm.D., BCPS
Linda M. Spooner, Pharm.D., FCCP, FASHP, BCPS-AQ ID
Bryant B. Summers, Pharm.D., BCPS
Robyn Teply, Pharm.D., MBA, BCACP 

The American College of Clinical Pharmacy, ASHP, and the authors thank the following individuals for their careful review: 

HIV I chapters:

Jennifer Le, Pharm.D., MAS, FCCP, FCSHP, FIDSA, BCPS-AQ ID
Mary Wun-Len Lee, Pharm.D., FCCP, BCPS
Marisel Segarra-Newnham, Pharm.D., MPH, FCCP, BCPS, BCIDP

Hepatitis I chapters:

H. Gwen Bartlett, Pharm.D., BCPS, BCCCP, BCCP
Marisel Segarra-Newnham, Pharm.D., MPH, FCCP, BCPS, BCIDP 

HIV and Hepatitis I features:

Jennifer Le, Pharm.D., MAS, FCCP, FCSHP, FIDSA, BCPS-AQ ID
Ralph H. Raasch, Pharm.D., FCCP, BCPS 


In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support and the Accreditation Council for Pharmacy Education’s Standards for Commercial Support, ASHP and the American College of Clinical Pharmacy require that all individuals involved in the development of activity content disclose their relevant financial relationships. A person has a relevant financial relationship if the individual of his or her spouse/partner has a financial relationship (e.g. employee, consultant, research grant recipient, speakers bureau, or stockholder) in any amount occurring the in the last 12 months with a commercial interest whose products or series may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on the content. 

All faculty and planners for ASHP education activities are qualified and selected by ASHP and required to disclose any relevant financial relationships with commercial interests. ASHP identifies and resolves conflicts of interest prior to an individual’s participation in development of content for an educational activity. Anyone who refuses to disclose relevant financial relationships must be disqualified from any involvement with a continuing pharmacy education activity. 

Consultancies: David E. Koren (Gilead Sciences, Inc.); Wesley D. Kufel (Theratechnologies); Michelle T. Martin (AbbVie; Gilead Sciences; Merck); Neha S. Pandit (Maryland AIDS Drug Assistance Program); Jason J. Schafer (Theratechnologies); Robyn Teply (AbbVie Inc.; Gilead Sciences, Inc.); Alice Tseng (ViiV; Gilead; Abbvie Canada); Elyse Tung (Gilead; ViiV Healthcare) 

Grants: Islam Ghazi (Merck and Co.; Achaogen; Astelas); David E. Koren (Gilead Sciences, Inc.); Wesley D. Kufel (Melinta Therapeutics); Sarah M. Michienzi (Merck); Patricia Poole (Gilead Pharmaceuticals; Cystic Fibrosis Foundation); Jason J. Schafer (Merck [two grants]); Robyn Teply (Gilead Sciences, Inc.); Alice Tseng (Abbvie; Merck Canada; ViiV; Gilead) 

Honoraria: Christina M. Madison (Janssen Therapeutics); Robyn Teply (Gilead Sciences, Inc.; AbbVie, Inc.); Alice Tseng (Gilead Canada; Merck Canada); Elyse Tung (Gilead; Integritas Communications) 

All other planners, presenters, and reviewers of this session report no financial relationships relevant to this activity. 

Methods and CE Requirements

Activities consist of educational materials, assessments, and activity evaluations. In order to receive continuing pharmacy education credit, learners must:

  • Complete the attestation statement
  • Review all content
  • Complete and pass the assessments
  • Complete the evaluations 

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity. 

System Technical Requirements

Courses and learning activities are delivered via your Web browser and Acrobat PDF. For all activities, you should have a basic comfort level using a computer and navigating web sites. 

View the minimum technical and system requirements for learning activities. 


These activities were developed by ASHP and ACCP.